Itolizumab, Drugs Monitor

(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS

April 29, 2021

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1905794 CTRI/2020/05/024959- Patients were randomized (2:1) to Arm-A (best supportive care [BSC]+Itolizumab) and Arm-B (BSC).… Continue reading "(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS"

(12 Dec 2020) Itolizumab- reduced IL‐6 level and patients showed pulmonary improvement

December 14, 2020

Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab https://doi.org/10.1002/cti2.1218 Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2/FiO2… Continue reading "(12 Dec 2020) Itolizumab- reduced IL‐6 level and patients showed pulmonary improvement"

(02 Dec 2020) Itolizumab- efficiently controls immune hyperactivation

December 5, 2020

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1 CTRI/2020/05/024959- Eligible patients were randomized (2:1) to arm A (best supportive care + Itolizumab)… Continue reading "(02 Dec 2020) Itolizumab- efficiently controls immune hyperactivation"

(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality

October 31, 2020

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19 https://doi.org/10.1159/000512210 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody in Cuba. All patients had underlying medical conditions.… Continue reading "(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality"

(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality

August 1, 2020

Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 https://doi.org/10.1101/2020.07.24.20153833 To preliminary assess the effect of itolizumab (CT-RPCEC00000311), a control group was selected among the Cuban COVID-19 patients, which did not receive immunomodulatory therapy. Control… Continue reading "(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality"

Tag: Itolizumab

(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS

(12 Dec 2020) Itolizumab- reduced IL‐6 level and patients showed pulmonary improvement

(02 Dec 2020) Itolizumab- efficiently controls immune hyperactivation

(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality

(30 July 2020) Itolizumab- associated with a reduction in the COVID-19 disease worsening and mortality